Gene Therapy for ALS: Progress and prospects

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 11-12, 2006, Pages 1122-1127

  Azzouz, Mimoun ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

ALS; Animal model; Gene Therapy; Motor neuron; Viral vector

Indexed keywords

ARIMOCLOMOL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CELECOXIB; CREATINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MINOCYCLINE; NEUROPROTECTIVE AGENT; NEUROTROPIC AGENT; RECOMBINANT PROTEIN; RILUZOLE; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOVIRUS VECTOR; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; HUMAN; HUNTINGTON CHOREA; LENTIVIRUS VECTOR; MOTOR NEURON DISEASE; NERVOUS SYSTEM; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA STABILITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS STRAIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; RNA INTERFERENCE; SUPEROXIDE DISMUTASE;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 33750972592     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.05.003     Document Type: Review

References (85)

1. Deglon N., and Hantraye P. Viral vectors as tools to model and treat neurodegenerative disorders. J. Gene Med. 7 (2005) 530-539
2. Wong L.F., Goodhead L., Prat C., Mitrophanous K.A., Kingsman S.M., and Mazarakis N.D. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum. Gene Ther. 17 (2006) 1-9
3. Davidson B.L., and Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat. Rev., Neurosci. 4 (2003) 353-364
4. Deglon N., and Aebischer P. Lentiviruses as vectors for CNS diseases. Curr. Top. Microbiol. Immunol. 261 (2002) 191-209
5. Martin-Rendon E., Azzouz M., and Mazarakis N.D. Lentiviral vectors for the treatment of neurodegenerative diseases. Curr. Opin. Mol. Ther. 3 (2001) 476-481
6. Rohll J.B., Mitrophanous K.A., and Martin-Rendon E. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346 (2002) 466-500
7. Burkrinsky M.I., Haggerty S., and Dempsey M.P. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365 (1993) 666-669
8. Gallay P., Stitt V., and Mundy C. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J. Virol. 70 (1996) 1027-1032
9. Mazarakis N.D., Azzouz M., and Rohll J.B. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10 (2001) 2109-2121
10. Azzouz M., Martin-Rendon E., and Barber R.D. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22 (2002) 10302-10312
11. Bensadoun J.C., Deglon N., and Tseng J.L. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164 (2000) 15-24
12. Bienemann A.S., Martin-Rendon E., and Cosgrave A.S. Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Molec. Ther. 7 (2003) 588-596
13. Blomer U., Naldini L., and Kafri T. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71 (1997) 6641-6649
14. Naldini L., Blomer U., and Gage F.H. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11382-11388
15. Kordower J.H., Emborg M.E., and Bloch J. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
16. Balaggan K.S., Binley K., Esapa M., Iqball S., Askham Z., Kan O., Tschernutter M., Bainbridge J.W., Naylor S., and Ali R.R. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J. Gene Med. 8 (2006) 275-285
17. Dittgen T., Nimmerjahn A., Komai S., Licznerski P., Waters J., Margrie T.W., Helmchen F., Denk W., Brecht M., and Osten P. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 18206-18211
18. Azzouz M., Kingsman S.M., and Mazarakis N.D. Lentiviral vectors for treating and modeling human CNS disorders. J. Gene Med. 6 (2004) 951-962
19. Negre D., and Cosset F.L. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 84 (2002) 1161-1171
20. Mitrophanous K., Yoon S., and Rohll J.B. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6 (1999) 1808-1818
21. Poeschla E.M., Wong-Staal F., and Looney D.J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4 (1998) 354-357
22. Trono D. When accessories turn out to be essential. Nat. Med. 4 (1998) 1368-1369
23. Kim V.N., Mitrophanous K., Kingsman S.M., and Kingsman A.J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72 (1998) 811-816
24. Dull T., Zufferey R., and Kelly M. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
25. Wang G., Slepushkin V., and Zabner J. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J. Clin. Invest. 104 (1999) R55-R62
26. Stitz J., Muhlebach M.D., and Blomer U. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 291 (2001) 191-197
27. Deglon N., Tseng J.L., and Bensadoun J.C. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Genet. Ther. 11 (2000) 179-190
28. MacKenzie T., Kobinger G., and Kootstra N. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Molec. Ther. 6 (2002) 349-358
29. Watson D.J., Kobinger G.P., and Passini M.A. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Molec. Ther. 5 (2002) 528-537
30. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L., Mitrophanous K.A., Kingsman S.M., Carmeliet P., and Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
31. Kobinger G., Weiner D., Yu Q., and Wilson J. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19 (2001) 225-230
32. Wong L.F., Azzouz M., and Walmsley L.E. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Molec. Ther. 9 (2004) 101-111
33. Galimi F., and Verma I.M. Opportunities for the use of lentiviral vectors in human Gene Therapy. Curr. Top. Microbiol. Immunol. 261 (2002) 245-254
34. O'Rourke J.P., Hiraragi H., and Urban K. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Molec. Ther. 7 (2003) 632-639
35. Ralph G.S., Mazarakis N.D., and Azzouz M. Therapeutic gene silencing in neurodegenerative disease using interfering RNA. J. Mol. Med. 83 (2005) 413-419
36. Blomer U., Kafri T., and Randolph-Moore L. Bcl-xL protects adult septal cholinergic neurons from axotomized cell death. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2603-2608
37. Lo Bianco C., Ridet J., and Schneider B. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10813-10818
38. de Almeida L., Ross C., and Zala D. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22 (2002) 3473-3483
39. Moffat J., Grueneberg D.A., and Yang X. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
40. Rowland L.P. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch. Neurol. 58 (2001) 512-515
41. Williams D.B., and Windebank A.J. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin. Proc. 66 (1991) 54-82
42. Mulder D.W. Clinical limits of amyotrophic lateral sclerosis. Adv. Neurol. 36 (1982) 15-22
43. Rosen D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 364 (1993) 362
44. Gurney M.E., Pu H., and Chiu A.Y. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
45. Wong P.C., and Borchelt D.R. Motor neuron disease caused by mutations in superoxide dismutase 1. Curr. Opin. Neurol. 8 (1995) 294-301
46. Julien J. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104 (2001) 581-591
47. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev., Neurosci. 2 (2001) 806-819
48. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis, ALS/Riluzole Study Group. N. Engl. J. Med. 330 (1994) 585-591
49. Lacomblez L., Bensimon G., Leigh P., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet Neurol. 347 (1996) 1425-1431
50. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., and Hall E.D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
51. Li M., Ona V.O., Guegan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.P., and Przedborski S. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288 (2000) 335-339
52. Klivenyi P., Ferrante R.J., Matthews R.T., and Bogdanov M.B. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
53. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., and Wu d.C. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
54. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., and Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52 (2002) 771-778
55. Kieran D., Kalmar B., Dick J.R., Riddoch-Contreras J., Burnstock G., and Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat. Med. 10 (2004) 402-405
56. Przedborski S., Mitsumoto H., and Rowland L.P. Recent advances in amyotrophic lateral sclerosis research. Curr. Neurol. Neurosci. Rep. 3 (2003) 70-77
57. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., and Pestronk A. A clinical trial of creatine in ALS. Neurology 63 (2004) 1656-1661
58. Pontieri F.E., Ricci A., Pellicano C., Benincasa D., and Buttarelli F.R. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol. Sci. 26 (2005) 285-287
59. Weiss M.D., Weydt P., and Carter G.T. Current pharmacological management of amyotrophic corrected. lateral sclerosis and a role for rational polypharmacy. Expert Opin. Pharmacother. 5 (2004) 735-746
60. Wang L.J., Lu Y.Y., and Muramatsu S. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22 (2002) 6920-6928
61. Kaspar B., Llado J., and Sherkat N. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
62. Storkebaum E., Lambrechts D., Dewerchin M., and Moreno-Murciano M.P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8 (2005) 85-92
63. Kordower J.H., Palfi S., and Chen E.Y. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46 (1999) 419-424
64. Aebischer P., and Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci. 24 (2001) 533-540
65. Tuszynski M.H. Growth-factor Gene Therapy for neurodegenerative disorders. Lancet Neurol. 1 (2002) 51-57
66. Cisterni C., Henderson C.E., Aebischer P., Pettmann B., and Deglon N. Efficient gene transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced wit lentiviral vectors. J. Neurochem. 74 (2000) 1820-1828
67. Hottinger A.F., Azzouz M., and Deglon N. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J. Neurosci. 20 (2000) 5587-5593
68. Azzouz M., Le T., Walmsley L., Monani U., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H.M., and Mazarakis N.D. LentiVector-mediated SMN replacement in a mouse model of spinal muscular atrophy. The J. Clin. Investig. 114 (2004) 1726-1731
69. Ralph G.S., Radcliffe P.A., Bilsland L., Leroux M.A., Greensmith L., Mitrophanous K.A., Kingsman S.M., Mazarakis N.D., and Azzouz M. Silencing of mutant SOD1 using interfering RNA induces long term reversal of ALS in a transgenic mouse model. Nat. Med. 11 (2005) 429-433
70. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., and Aebischer P. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11 (2005) 423-428
71. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., and Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 22 (2004) 326-330
72. Gong D., and Ferrell Jr. J.E. Picking a winner: new mechanistic insights into the design of effective siRNAs. Trends Biotechnol. 22 (2004) 451-454
73. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., and Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32 (2002) 107-108
74. Sorensen D.R., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327 (2003) 761-766
75. Soutschek J., Akinc A., and Bramlage B. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
76. Davidson B.L., and Paulson H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3 (2004) 145-149
77. Miyagishi M., and Taira K. Development and application of siRNA expression vector. Nucleic Acids Res. (2002) 113-114 (Suppl)
78. Wiznerowicz M., and Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77 (2003) 8957-8961
79. Xia H., Mao Q., and Eliason S.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10 (2004) 1006-1010
80. Gonzalez-Alegre P., Bode N., Davidson B.L., and Paulson H.L. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J. Neurosci. 25 (2005) 10502-10509
81. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., and Mao Q. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5820-5825
82. Singer O., Marr R.A., Rockenstein E., and Crews L. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8 (2005) 1343-1349
83. Miller T.M., Kaspar B.K., Kops G.J., Yamanaka K., Christian L.J., Gage F.H., and Cleveland D.W. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. 57 (2005) 773-776
84. Miskin J., Chipchase D., Rohll J., and Beard G. A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors. Gene Ther. 13 (2006) 196-205
85. Sastry L., Xu Y., Duffy L., and Koop S. Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection. Hum. Gene Ther. 16 (2005) 1227-1236